（原标题：两个多月跌超8%，基金经理被爆在"赌"？申万菱信回应） 【导读】申万菱信行业精选基金成立两个多月跌超8%，基金经理被爆在"赌"？申万菱信基金回应 中国基金报记者 格林 日前，一位自称申万宏源证券底层员工的人士爆料称，被压任务买了申万菱信行业精选混合基金。该人 士说，虽然此前也有被压任务买基金陷入亏损的经验，但因为认可该基金的高分红思路，还是买了。不 过，该基金自建仓以来净值一路下跌。该人士对基金经理的操作提出了质疑：认为基金先追高新消费， 后又追高银行股，基金经理的操作与公司宣传的高股息方向不符，并认为基金经理在"赌"。 本报此前报道显示，贾成东是一位"基本面趋势投资者"。招商优质成长、招商行业精选是他此前的代表 作。Wind数据显示，他自2016年12月31日、2017年6月29日先后出任上述基金的基金经理，2024年6月 15日离任，任职期间两只基金的单位净值增长率分别达192.09%和140.27%。贾成东的个人管理规模一 度接近180亿元。 截至目前，贾成东尚未能在申万菱信基金复制过往的业绩。不过，也有业内人士表示，对于公募基金产 品而言，几个月时间尚短。 对此，申万菱信基金回应称，注意到市 ...

Group 1 - The innovative drug sector has experienced a strong upward trend since May, attracting significant investor attention [1][2] - Despite the rising market, there is a notable divergence in the investment pace of newly established active equity funds, with some accelerating their investments while others remain cautious [2][3] - As of June 18, seven active equity funds were established in the eight trading days since June 9, with six showing net value fluctuations [2] Group 2 - The Ping An Hong Kong Stock Connect Medical Innovation Select Fund, initially set to close on June 25, ended its fundraising early on June 9, with a final scale of 249 million yuan [2] - The Dongfang Alpha Health Industry Fund also shortened its fundraising period from six to two trading days, ultimately raising 11 million yuan [2] - The performance of newly established funds varies, with the Invesco Great Wall Medical Industry Fund achieving a return of 27.01% as of June 17, leading among newly established funds [4][5] Group 3 - The fund manager of the Invesco Great Wall Medical Industry Fund indicated that the fund was established during a low point in the medical industry, but they remain optimistic about the sector [5][6] - The fund's portfolio had an 83.11% holding position by the end of Q1, with nearly 40% in Hong Kong stocks [5] - The manager anticipates 2025 to be a year of recovery for the industry, driven by reforms in commercial health insurance and the maturation of innovative drug companies [6] Group 4 - Despite the strong performance of the innovative drug sector, there are warnings about the inherent risks in drug development, including low success rates and high capital requirements [7] - The average success rate for drug development projects is only 10%, with a lengthy development cycle of around 10 years and costs reaching 1 billion yuan [7] - The ability of Chinese pharmaceutical companies to conduct clinical trials and commercialize products internationally still requires improvement [7]